Those who have received one dose of the monovalent Pfizer vaccine are eligible for two doses of the bivalent Pfizer vaccine, and those who have received two or three doses of the monovalent Pfizer are eligible for one dose of the bivalent Pfizer vaccine. If you are immunocompromised: If you are 6 months or older and unvaccinated, you are eligible for three doses of the bivalent Pfizer vaccine. People ages 65 years and older who have gotten one dose of a bivalent vaccine are eligible for another dose of the bivalent Pfizer vaccine to be given at least four months after getting the previous one. If you have received one or more doses of a monovalent vaccine, you are eligible to get one dose of the bivalent Pfizer vaccine starting at least eight weeks after receiving your last monovalent shot. People ages 5 and older: If you are unvaccinated, you are eligible for a single dose of the bivalent Pfizer vaccine.Children who have gotten three doses of the monovalent Pfizer vaccine are eligible for a single dose of the bivalent shot starting eight weeks after receiving the monovalent vaccine. Those who have received two doses of the monovalent Pfizer vaccine are eligible for one dose of the bivalent vaccine, which should be given at least eight weeks after receiving the monovalent vaccine. If they have received one dose of the monovalent Pfizer vaccine, they are eligible for two doses of the bivalent vaccine with the first dose three to eight weeks after the monovalent dose, and the second shot at least eight weeks later. Children between 6 months and 4 years: If your child is unvaccinated, they are eligible for three doses of the bivalent vaccine with the first two doses three weeks apart and the third dose at least eight weeks later.Who can get it: People 6 months and older. The original shot (called the monovalent, because it targeted only one strain) is no longer available in the U.S. They are called bivalent because they were updated to protect against two virus strains: the original one and the BA.4/BA.5 Omicron subvariants. The bivalent shots, first authorized in 2022, are now the only mRNA COVID-19 shots available in the U.S. recommended updated mRNA (bivalent) shots for most inoculations, including primary vaccinations and additional (booster) shots. Options for getting the Pfizer-BioNTech vaccine changed in April 2023, when the U.S. It must be stored in freezer-level temperatures, which can make it more difficult to distribute than some other vaccines. This is a messenger RNA (mRNA) vaccine, which uses a relatively new technology. Before that, it was the first COVID-19 vaccine to receive FDA Emergency Use Authorization (EUA) back in December 2020, after the company reported that its vaccine was highly effective at preventing symptomatic disease. The Pfizer-BioNTech vaccine (brand name: Comirnaty) was granted full Food and Drug Administration (FDA) approval in August 2021 for people ages 16 and older. We mapped out a comparison of the most prominent COVID-19 vaccines. In the U.S., infants, children, and adults ages 6 months and older are eligible to be vaccinated, according to the Centers for Disease Control and Prevention (CDC).Īs the SARS-CoV-2 virus mutates and new variants continue to emerge, it’s important to keep up with how well the vaccines are performing, but it’s also a daunting task, given the flood of information (and misinformation) coming at us from so many directions. The good news is that vaccines are still expected to be effective at preventing severe disease, hospitalization, and death from COVID-19. Because information about COVID-19 changes rapidly, we encourage you to visit the websites of the Centers for Disease Control & Prevention (CDC), World Health Organization (WHO), and your state and local government.ĬOVID-19 is now in its fourth year, and the Omicron variant and its subvariants are still driving infections in cases in the United States. Information in this article was accurate at the time of original publication. ![]() ![]() ![]() Adults ages 18 years and older who received one or two J&J COVID-19 vaccine doses are recommended to receive one bivalent mRNA dose (Moderna or Pfizer-BioNTech) at least two months after completion of the previous dose. The CDC says that people ages 18 years and older who received one dose of the J&J vaccine should be considered to have received a single-dose J&J primary series. Note: The Johnson & Johnson (Janssen) COVID-19 vaccine is no longer available in the U.S.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |